原发性肝癌根治性切除术后的综合治疗

Comparehensive treatment of primary liver cancer after radical resection

目的探讨原发性肝癌根治性切除术后,实施TACE、生物治疗及PEI、RFA对肝内肿瘤复发率及生存率的影响。方法将42例原发性肝癌根治性切除术后患者分成观察组和对照组,观察组22例行综合治疗,包括:术后TACE、生物治疗及PEI、RFA,对照组20例仅予对症、支持治疗。对两组病例的1、2年肝内肿瘤复发率和生存率分别进行X2检验。结果观察组1、2年的肝内复发率分别为13.6%,31.8%,对照组为40.0%及65.0%,而观察组1、2年生存率90.9%,68.2%,对照组为65.0%及35.0%。两组有显著性差异(P<0.05)。结论原发性肝癌根治性切除术后联合TACE、生物治疗及PEI、RFA的综合治疗方案可降低肝内复发率,提高生存率。

Objective To explore the effect of neoadjuvant combined postoperative therapy on patients with hepatocellular carcinoma after radical resection. Methods 42 postoperative case divided into 2 groups at random with 22 cases receiving hepatic artery chemotherapy and biotherapy, and 20 cases receiving supporting treatment only. Results The intrahepatic tumor recurrence rate at 1 year and 2 year in treatment group was 13.6% and 31.8%,compared with 40.0% and 65.0% in control group(p<0.05). The survival rate in the former was 90.9% and 68.2% respectively, compared with that of 65.0% and 35.0% in the later (p<0.05). Conclusions This neoadjuvant combined postoperative theropy effects a low recurrency and long survival in HCC patients after radical resection.